Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin in advanced breast cancer
NCT03052634Phase 2Completed
- Sponsor
- RemeGen
- Start
- Dec 2016
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of disitamab vedotin in breast cancer (4 arms), sponsored by RemeGen. Primary endpoint: Recommended Phase 2 Dose at 2 years. Started Dec 2016; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03052634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052634.